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The wrong suspect?
P
atients with Parkinson’s disease 
(PD) suffer a specifi  c loss of dop-
aminergic neurons from the mid-
brain region that controls motor function. 
The exact mechanism of this selective 
neurodegeneration is unclear, though many 
lines of evidence point to dysfunctional 
mitochondrial complex I as one root cause 
of the disease. Yet Choi et al. now sug-
gest that defective regulation of micro-
tubules may be responsible for at least 
some cases of PD (1).
Mitochondria were fi  rst implicated in 
PD when drug users in California devel-
oped Parkinson’s-like symptoms due to a 
contaminant in their heroin supply called 
MPTP (2). This chemical is metabolized in 
the brain into MPP  + , a compound that blocks 
oxidative phosphorylation by inhibiting 
mitochondrial complex I. Subsequently, 
other chemicals such as rotenone were 
shown to inhibit complex I and induce PD 
in animal models, and PD patients were 
found to have reduced levels of complex I 
activity. Moreover, several proteins linked 
to genetic forms of PD are involved in main-
taining normal mitochondrial function (3). 
But in 2008, Zhengui Xia and colleagues at 
the University of Washington in Seattle be-
gan to cast doubt on complex I’s guilt (4).
“We didn’t set out to prove anybody 
wrong,” says Xia. “We just wanted to do a 
quick experiment to provide genetic proof 
that complex I inhibition 
causes dopaminergic neuron 
death.” Xia and colleagues 
therefore examined mice lack-
ing an essential subunit of 
complex I called Ndufs4. To 
their surprise, dopaminergic 
neurons from these mice were 
healthy and remained sensi-
tive to MPP  +  - and rotenone-
induced death (4).
This suggested that com-
plex I inhibition is insuffi  cient 
to cause dopaminergic nerve apoptosis. 
Confi  rming this, Choi et al. found that an-
other complex I inhibitor, piericidin A, has 
no effect on dopaminergic cell survival (1). 
“So if it’s not by inhibiting complex I, what 
is the mechanism [by which rotenone and 
other drugs kills these neurons]?” says Xia.
The researchers turned their attention to 
another property of rotenone: the drug also 
depolymerizes microtubules. Cultured dop-
aminergic neurons were spared from rote-
none-induced death if they were co-treated 
with the microtubule-stabilizing drug taxol. 
On the other hand, the depolymerizing 
agent colchicine was as deadly as rotenone 
to dopamine-producing neurons.
But why do these microtubule-disrupting 
drugs only kill dopaminergic neurons and 
not other types of nerve cells? “Microtu-
bule disassembly impairs dopamine re-
lease, so dopamine accumulates in the cell,” 
explains Xia. Excess cytoplasmic dop-
amine may then be oxidized, 
producing reactive oxygen 
species (ROS) that induce cell 
death. Taxol prevented rote-
none from increasing dop-
amine and ROS levels, and 
drugs that inhibit either dop-
amine synthesis or ROS pro-
tected neurons from rotenone-
induced death.
Rotenone may have an 
additional dirty trick up its 
sleeve. Choi et al. think that 
the drug also inhibits VMAT2, the protein 
that transports dopamine into synaptic 
vesicles. Boosting VMAT2 expression 
promoted dopaminergic neuron survival, 
presumably by removing excess dopamine 
from the cytoplasm, thereby limiting the 
neurotransmitter’s oxidation.
Yet mitochondrial complex I isn’t a com-
pletely innocent bystander. Dopaminergic 
neurons lacking Ndufs4 are actually more 
sensitive to rotenone than wild-type neurons. 
The loss of complex I causes its substrate, 
NADH, to accumulate, which in turn boosts 
the activity of the enzyme that synthesizes 
dopamine. “The basal dopamine level is 
higher in knockout cells,” explains Xia. “It’s 
not high enough to cause a problem by itself, 
but it synergizes with rotenone’s inhibition 
of microtubules and VMAT2.”
Simultaneous inhibition of mitochon-
drial and microtubule function by different 
environmental and genetic factors may 
therefore contribute to PD. Indeed, several 
proteins linked to familial PD can infl  uence 
the microtubule cytoskeleton. The E3 ubiq-
uitin ligase Parkin, for example, targets - 
and -tubulin, as well as dysfunctional 
mitochondria, for degradation. Zhengui Xia 
says she now wants to confi  rm her group’s 
fi  ndings in vivo. Ndufs4-knockout mice die 
at 7 weeks, so conditional knockout models 
will be needed to check for PD-like symp-
toms in older animals.
1. Choi, W.-S., et al. 2011. J. Cell Biol. doi:10.1083/
jcb. 201009132.
2. Langston, J.W., et al. 1983. Science. 219:979–980.
3. Abou-Sleiman, P.M., et al. 2006. Nat. Rev. 
Neurosci. 7:207–219.
4. Choi, W.S., et al. 2008. Proc. Natl. Acad. Sci. USA. 
105:15136–15141.
(Left to right) Won-Seok Choi, Richard Palmiter, and Zhengui Xia show that rotenone—a drug 
that induces Parkinson’s disease in rodents—selectively kills dopaminergic neurons by 
depolymerizing microtubules, leading to the accumulation of dopamine and cytotoxic reactive 
oxygen species. Rotenone and other factors have been thought to cause Parkinson’s disease 
by inhibiting mitochondrial complex I, but Choi et al. demonstrate that neither genetic nor 
chemical inhibition of complex I is sufﬁ  cient to cause dopaminergic cell death. The substantia 
nigra of mice lacking the complex I subunit Ndufs4 (right) contains the same number of tyrosine 
hydroxylase–positive dopaminergic neurons as wild-type mice (left).
“Microtubule 
disassembly 
impairs 
dopamine 
release, so 
dopamine 
accumulates 
in the cell.
Parkinson’s disease may be caused by microtubule, rather than mitochondrial complex I, dysfunction.
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